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The lack of ex-ante evaluation of germplasm in genebanks has been the single 
most prevalent and long-standing complaint of plant breeders about the management of 
genebanks.  Advances in biotechnology offer the possibility of faster, cheaper, and more 
efficient evaluation methodologies.  Will these new technologies favor ex-post 
evaluation, as some expect, or will it lead to more ex-ante evaluation?  Will it also lead to 
earlier development of varieties with disease resistance traits in anticipation of actual 
infestations?  Will the prospect of further advances in biotechnology favor delay of 
evaluation and development?  This paper addresses these questions in the case of 
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THE TIMING OF EVALUATION OF GENEBANK ACCESSIONS AND THE 
EFFECTS OF BIOTECHNOLOGY 
 





Plant genetic resources have provided basic building blocks for the improvement 
of plant varieties and recent advances in biotechnology have opened up more possibilities 
for the use of these resources in crop improvement.  Collections of germplasm (the 
‘material that controls heredity’, Witt 1985, p.8) for conservation purposes in ex-situ 
genebanks have been greatly expanded over the past decades.  However, though the 
principal justification for such extensive germplasm conservation is for its use in crop 
improvement, materials in genebanks are not being used extensively by plant breeders 
(Wright 1997).  One frequently cited obstacle to greater utilization is the lack of 
information useful to breeders regarding the samples of germplasm held as accession in 
ex-situ collections. 
Evaluation data
1 are of the greatest value to plant breeders seeking particular 
genetic traits for crop improvement, but only a small fraction of samples in the genebank 
                                                 
* Bonwoo Koo is an assistant research economist supported by IFPRI through the 
Agricultural Issues Center of the University of California; Brian Wright is a professor in 
the Department of Agricultural and Resource Economics at the University of California, 
Berkeley.
 
1 The types of information regarding germplasm can be broadly categorized as 
passport data, characterization data, and evaluation data (Office of Technological 
Assessment 1987).  Passport data include information on the origin and environmental 
conditions of the material.  Characterization data include environment-insensitive traits 
such as morphological, biochemical, and molecular information, while evaluation data 
include environment-sensitive traits such as yield potential and disease resistance.  
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network have evaluation data.
2  Even among the collections with evaluation data, the 
information currently provided by genebanks is often perceived as inadequate.  While 
this situation has led many plant breeders to demand more complete evaluation of 
genebank materials for crop improvement (Duvick 1984, Peeters, and Galwey 1988; 
Goodman 1990; and NRC 1993), this viewpoint is not universally shared (see for 
example Frankel 1989). 
Existing studies on the use and management of genebank collections of genetic 
resources deal largely with the optimal size of ex-situ genebank collections (Brown 1989 
and Chang 1989), the value of genetic resources (Evenson 1996 and Simpson et al. 
1996), or the optimal search strategy for useful traits (Gollin et al. 1997).  However, the 
neglected issue of the timing of evaluation and utilization of genebank materials has 
become an important consideration for genebank managers, especially in the current 
rapidly changing technological environment.  
The timing of identifying and isolating useful traits has been an important factor 
in crop improvement.  For example, when the Russian wheat aphid began to affect the 
United States in the late 1980s, the damage might have been mitigated if the sources of 
resistance had already been identified.  After the disease broke out, searches among 
wheat varieties in the United States Department of Agriculture (USDA) collection 
yielded almost no useful materials, and the resistance was later found from a number of 
varieties from Iran and Russia (Robinson 1994).  Lack of preparation might have  
                                                 
2 Although this point is frequently made, we must go back to Peeters and 
Williams (1984) for hard data.  They report that 65 percent of the samples in the 
genebank network have no passport data, 80 percent have no characterization data, 95 
percent have no evaluation data, and only one percent has extensive evaluation data.  
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contributed to the estimated economic damage of $670 million by 1991 (Russian Wheat 
Aphid Task Force 1991).  On the other hand, when barley stripe rust fungus devastated 
Europe and South America in the 1970s, plant breeders in the United States worked to 
identify sources of resistance to the disease and could effectively cope with it when the 
disease reached the United States in 1990 (Kurt Leonard, personal communication 1999). 
In this paper, we focus on the cases similar to those just mentioned, in which a 
trait for resistance to a pest or disease is already known but has not yet infested the 
relevant crop, and address the following questions on evaluation and utilization of 
genebank collections.  When is it optimal to evaluate genebank material for a trait: i.e., ex 
ante in anticipation of an infestation, or ex post after infestation of the disease in the 
relevant crop?  When is it optimal to develop a new variety incorporating the trait?  What 
is the effect of advances in biotechnology on the timing of evaluation and development?  
And how is the timing of evaluation and development changed when there is a possibility 
of a further technological breakthrough in either of these functions in the future? 
Resistance is often achieved by transferring desirable traits, found either in 
genebank collections or genetic stocks, into existing varieties by conventional breeding or 
other means such as wide crossing or genetic transformation.  Identification of resistance 
before the outbreak of a disease can be difficult and costly.  If an outbreak of a disease 
occurs, the development of a new disease-resistant variety will be faster if the gene for 
the resistance trait has already been located.  However, there is some chance that the 
disease never occurs or occurs in the remote future, in which case the money spent for 
evaluation is, in hindsight￿i.e., ex post￿wasted.  If evaluation is started after the 
disease occurs, excess ex-ante evaluation is avoided.  However, the social losses due to  
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damages from the disease will be incurred during the delay until a new variety is 
developed. 
In a simple model of evaluation and development, we find that if a disease has 
sufficiently low likelihood of occurrence, it is cost effective to delay evaluation of the 
trait until the disease occurs.  In addition, the benefit from ex-ante evaluation turns out to 
be the largest when the hazard rate of the disease is at an intermediate, rather than at the 
maximum, rate.  Several recent innovations in tools and methods have made evaluation 
for resistance traits and development of useful cultivars incorporating these traits cheaper 
and faster.
3  Such a cheaper and faster response might seem to favor ex-post evaluation.  
But we show that in economic terms advances in biotechnology that reduce the cost or 
increase the speed of evaluation or development tend to favor ex-ante evaluation more 
than ex-post.  
Current advances in biotechnology imply that further innovations are likely.  
Well-known result of real option theory is that uncertainty about costs tends to favor 
delay in an investment (Arrow and Fisher 1974; McDonald and Siegel 1986; and Dixit 
and Pindyck 1994).  Does this imply that a further anticipated breakthrough in the 
technology of evaluation and development tends to favor delay, in contrast to the effect 
of a current breakthrough?  The usual real option effect is observed in our model for the  
                                                 
3 Molecular genetic techniques such as restriction fragment length polymorphism 
(RFLP), random amplified polymorphic DNA (RAPD), and amplified fragment length 
polymorphism (AFLP), are used to identify specific genotypes and agronomic traits of 
interest and to “fingerprint” individual accessions.  These techniques, together with cell 
culture techniques and transformation techniques involving recombinant DNA (rDNA), 
are also used for the development of new plant varieties by facilitating the transfer of the 
desired genes and the development of new cultivars in a fast, reliable, and cost-effective 
way (Rao and Riley 1994).  
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case of innovation in evaluation.  But we show that anticipation of the possibility of a 
technological breakthrough in development may speed up, rather than delay, the timing of 
evaluation and development.  We conclude that both the level and rate of technological 
progress in development may justify advancing the timing of the evaluation of genebank 
accessions as well as the development of cultivars incorporating newly identified traits. 
Section 2 introduces the model of the expected costs under different evaluation 
and development alternatives, and examines the factors that affect the timing of 
evaluation.  Section 3 analyzes the effect of current advances in biotechnology on the 
timing of evaluation and development, and section 4 extends the model to analyze the 
implications of dynamic technological changes and compares our result with existing 
arguments on real option theory.  Concluding remarks follow in Section 5.   
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2. THE MODEL OF EVALUATION AND DEVELOPMENT 
ASSUMPTIONS 
We propose a highly stylized model that abstracts from many biological details. 
We consider the search for a single qualitative trait
4 (say, a resistance to a certain disease) 
for a specific environment in a given ex-situ collection of germplasm, either ex ante or ex 
post.
5  For simplicity, we assume resistance is conferred by a single gene, and (contrary 
to common experience) that single-gene resistance retains its effectiveness forever.  The 
evaluation process ceases as soon as a variety with the targeted gene is identified.
6  
We postulate a two-stage process for the development of a new disease resistant 
variety: the search (or evaluation) process in which a genebank conducts a search in its 
collection for a disease resistant trait, and the development process in which a genebank 
develops a new variety, expressing the evaluated gene, for release to farmers.
7  We 
assume that the search process must be completed prior to the initiation of the 
development process. 
                                                 
4 Frankel (1989) categorizes two kinds of traits of concern to plant breeders; 
qualitative traits and quantitative traits.  Disease-resistance traits are typically qualitative, 
and are among the most sought-after traits in germplasm collections. 
5 Ex-post evaluation is often performed by plant breeders, but for simplicity of 
exposition we assume the genebank manager conducts the search. 
6 Our search process is close to the process of screening, assumed by Simpson et 
al. (1996).  In practice, some sources of a trait may be more desirable as breeding 
materials than others, so evaluation may continue after the first positive result of the 
search (Evenson and Kislev 1976 and Gollin et al. 1997).  We ignore this consideration 
here. 
7 Gollin et al. (1997) explicitly consider the prebreeding process by which 
resistance genes found in the search process are transferred into a breeding program 
before the development process.  Our model assumes that the prebreeding process is a 
part of the development process.  
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A disease breaks out at a random future period t, according to a Poisson disease 
hazard rate l.  By spending a constant flow search cost c, the genebank finds the targeted 
gene at time s after the initiation of evaluation, according to a Poisson discovery rate f.  
Once a disease occurs, society suffers losses from the disease until the development of a 
new disease resistant variety.
8  It takes l periods with a constant development cost m per 
period to develop a new variety,
9 and the disease cost due to the delayed introduction of a 
new variety is d per period of infestation.  Diffusion of the disease and of the new variety 
after development are, for simplicity, assumed immediate.  The genebank is assumed to 
be risk neutral and the discount rate is r. 
Figure 1 shows the decision tree of a genebank manager on the timing of 
evaluation and development.
10  For simplicity, we ignore the option of “no action” by 
assuming that the cost from a disease is high enough to justify the development of a new 
variety once a disease occurs. 
                                                 
8 This assumption implies that we ignore the possibility of other types of disease 
control such as chemical pesticides.  Some soil-borne diseases may naturally decline in 
severity after seven to ten years of continuous infestation, and in other cases crop rotation 
can be used as a means of disease control (Leonard, personal communication 1999).  
Finally, substitution of a nonsusceptible crop can reduce the losses caused by the disease.  
The flow cost of infestation could be modified to recognize these mitigating factors. 
9 Similar qualitative results are derived by assuming a stochastic development 
process. 
10 Squares in Figure 1 indicate the decision nodes for the genebank manager, and 
the circle indicates the chance node with exogenously determined probabilities.  
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Figure 1: Decisions on the timing of evaluation and development 
 
 
The first decision that a genebank manager should make in period zero, prior to 
an infestation, concerns the timing of evaluation; i.e., whether to evaluate immediately 
(ex ante) or delay the evaluation until the infestation of a disease (ex post).  If he chooses 
to delay evaluation, evaluation and development should (by assumption) follow in 
sequence immediately after infestation.  If he chooses ex-ante evaluation in period zero 
and the search for the traits succeeds in period s, he must decide the timing of 
development if the infestation has not yet occurred (s < t).  His decision then is whether 
to develop immediately, before the disease infestation, or to delay until infestation 
[Develop immediately] 
[Delay evaluation until 
disease infestation at time t] 
If s < t 
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Development at s 
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[Delay development 
until disease 
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If G < 0, ex-post evaluation/development incurs lower cost and delaying 
evaluation is optimal.  The first term on the RHS of (2) is the difference in the expected 
search cost, which is nonpositive since the search cost is always incurred, and incurred 
earlier, under ex-ante evaluation.  The second term, the difference in the expected 
development cost, is also nonpositive for a positive discount rate since development 
occurs earlier when evaluation is ex ante.  The third term is the difference in the expected 
disease cost, which is nonnegative due to the longer period of delay under ex-post 
evaluation.  
For a rare disease (l ﬁ 0), the cost difference is negative and ex-post evaluation 
is more cost effective.  The expected development cost and the disease cost under both 
alternatives vanish when the disease hazard rate l approaches zero, and only the expected 
search cost remains as an important consideration.  If the disease hazard rate is high (l ﬁ 
¥), the cost difference function G approaches zero, implying that there is vanishing 
difference in the expected costs.  Since the disease is expected to occur very soon, the  
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expected timing of the evaluation process as well as the development process is almost 
the same for both alternatives and thus the cost difference is negligible.  
Proposition 1—Optimal Timing of Evaluation and Disease Hazard Rate. 
Given ex-post development at the second stage, ex-post evaluation is optimal if 
disease hazard rate is below a critical level l1 and search cost is less than a critical level 
c1. 
Proof 
From equation (2), we can derive the range of the disease hazard rate in which ex-






” l < l <
) (
0 1  (3) 
where K ” [d(1 – L) – mL] > 0.  If l is less than the cutoff level l1, ex-post evaluation 
brings lower expected cost.  In addition, the search cost should be less than c1 to make l1 
positive. 
  r K c c / 1 f ” <  (4) 
Q.E.D. 
From the genebank manager’s point of view, proposition 1 implies that it is better not to 
evaluate accessions ex ante for a gene (or trait) that is expected to be used rarely in the 
future.  For a rare disease, the use of the evaluated resistant gene will be long delayed and 
the search cost incurred at the current time is large relative to the expected present value 
of the benefits. For a disease that is more likely to cause an infestation soon, ex-ante 
evaluation may be preferred if it is cheap enough, because it reduces the expected disease 
cost. But the advantage of ex-ante evaluation is not monotonic in the disease hazard rate.  
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Proposition 2—Ex-Ante Evaluation and Disease Hazard Rate. 
The benefit from ex-ante evaluation is maximized when the disease hazard rate is 
at an intermediate level. 
Proof 
The first-order condition of function G of equation (2) is 
  0
) ( ) )( (




l + f + l + f +





r c K r r r cr cr K G
  
When equation (4) holds, only one root of l that satisfies the condition of the above 
equation is positive and finite.  Thus, the rate l
*, which is associated with the maximum 
cost difference G (or, maximum net benefit from ex-ante evaluation) is calculated as 
  0







where J ” K(K + c)r(r + f)f
2 > 0.  The second order condition is satisfied around l
*. 
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r cr cr K G
 Q.E.D. 
If, in addition to the costs accounted for above, there is a fixed cost associated with the 
decision to evaluate ex ante (e.g., in terms of the genebank manager's time), then the 
value l
* gives guidance to a genebank manager in forming priorities regarding evaluation 
for resistance to various potential diseases.  Ceteris paribus, diseases with hazard rates 
near l
* are the best candidates for ex-ante evaluation.  If a disease rarely occurs (i.e., low 
l), the advantage of early evaluation is less attractive.  If a disease is expected to occur 
soon, on the other hand, the trait will be evaluated soon under either approach and the 
importance of decision timing is reduced.  
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Figure 2: A cost difference function G 
 
Figure 2 shows the graph of a typical cost difference as a function of the disease 
hazard rate.  The value l1 defined in (3) is the cutoff disease hazard rate below which ex-
post evaluation is preferred.  The size of the cost difference G for l > l1 indicates the 
degree to which ex-ante evaluation is preferred: i.e., the larger the value, the better the 
ex-ante evaluation approach in terms of cost effectiveness.  The maximum advantage of 
ex-ante evaluation is attained at l
*.  
 G(l)








3. THE EFFECTS OF ADVANCES IN BIOTECHNOLOGY 
Recently, innovations in biotechnology have occurred that can reduce the cost of 
the search or development process and/or speed up the processes.  Here we consider how 
such innovations affect the decision on the timing of evaluation and development.  We 
identify two types of technological changes for our analysis.  The first type includes 
technologies that primarily affect the search process such as molecular genetic 
techniques, while the other type includes those that mainly affect the development 
process, such as transformation technology, cell culture techniques, and the use of 
molecular markers to identify transformed cultivars in the breeding process. 
ADVANCES IN BIOTECHNOLOGY AFFECTING THE SEARCH PROCESS 
The effects of the changes in the flow search cost c and the discovery rate f on the 
























l ” l r r
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 (6b) 
A higher search cost c favors ex-post evaluation (equation (6a)).  The search cost 
differs by the types of traits to be evaluated.  For example, Peeters and Williams (1984) 
report that the per-unit evaluation cost for rhizoctonia resistance in sugarbeet was $175, 
while the cost of evaluating nematode resistance was only $60 per unit.  If the cost and 
probability of an outbreak of each disease were the same and if there were no economies 
of scope in evaluation (ignored here), then ex-ante evaluation becomes relatively more 
attractive for nematode resistance.  
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A high discovery rate f favors ex-ante evaluation in terms of the search cost due 
to the discount factor, but it also favors ex-post evaluation since it is less costly to delay 
evaluation when discovery is fast.  Equation (6b) shows that the first effect dominates the 
second effect around the cutoff rate l1.  If modern tools of biotechnology such as genetic 
marker techniques and new genomic information reduce the time spent for the evaluation 
process of certain resistance traits sufficiently, without increasing the flow search cost, 
this should tend to favor ex-ante evaluation of germplasm for such traits. 
ADVANCES IN BIOTECHNOLOGY AFFECTING THE DEVELOPMENT PROCESS 
The effects of the changes in the development period l and the development cost 
m on the cost difference are 
  0
) )( )( (
1
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A low development cost favors ex-ante evaluation (equation (7a)).  Since timing 
of the development process under ex-ante evaluation is earlier than that under ex-post 
evaluation, a reduction in the development cost has a larger impact when evaluation is 
made ex ante.  Modern technologies that reduce the development cost will favor ex-ante 
evaluation.  On the other hand, if strict government regulations on the use of 
biotechnology increase the development cost and delay the introduction of a new variety, 
ex-post evaluation will be more encouraged. 
A shorter development period l decreases the expected development and disease 
costs under both approaches. However, the rate of decrease in the expected costs under 
ex-ante evaluation is higher than that under ex-post evaluation, because the saved costs  
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are less discounted for ex-ante evaluation.  Modern genetic engineering techniques that 
speed up the development process favor ex-ante evaluation.  We can summarize these 
implications of advances in biotechnology as the following proposition. 
Proposition 3—Optimal Timing of Evaluation and Advances in Biotechnology 
Advances in biotechnology, which reduce the cost of the search or development 
process and/or speed up these processes, increase the value of ex-ante evaluation relative 
to ex-post evaluation.  
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Figure 3 illustrates the decision tree of a genebank manager when there exists an 
anticipated technological breakthrough in development.  The genebank manager now has 
additional decision nodes at the time of a technological breakthrough, u.  The decision in 
period zero is whether to evaluate immediately (ex-ante evaluation), or to delay, either 
until a technological breakthrough (“post-breakthrough” evaluation) or until disease 
infestation occurs (“post-infestation” evaluation).  Given ex-ante evaluation (i.e., the left 
branch in Figure 3), if a disease breaks out before finishing the evaluation (t < s), 
development must proceeds immediately after evaluation, by assumption.  If a 
technological breakthrough happens before finishing the evaluation and the disease has 
not yet broken out (u < s < t), he must decide whether to develop immediately (
0
0 A ) or to 
delay until the disease outbreak (
t A0).  If neither happens before finishing the evaluation 
(s < t and s < u), he can (i) delay development until the outbreak of a disease regardless 
of the technological breakthrough (
t A0), (ii) delay until the technological breakthrough 
(
u A0 ), or (iii) develop immediately (
0
0 A ).  
On the other hand, if the genebank manager decides to delay evaluation (i.e., the 
right branch in Figure 3), his decision depends on the relative timing of infestation and 
breakthrough.  If infestation occurs before a breakthrough (t < u), he begins evaluation 
immediately, followed by development.  Otherwise, the decision environment is the same 
as the previous case without a breakthrough possibility except for the decrease in the size 
of development cost.  One alternative is that the manager delays both evaluation and 
development until infestation even if the technological breakthrough has happened before 
the disease, in which case the expected cost is 
t
t P .  The second alternative is to evaluate  
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Figure 3: Decisions on the timing with a technological breakthrough 
 
after the breakthrough but to delay development until the disease infestation (
t
u P ), and 
the third is to develop immediately after the evaluation, even if the disease infestation has 
not yet occurred (
u
u P ).  The expected costs of each alternative are summarized in the 
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Ex-ante evaluation/post-infestation development 
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THE EFFECT OF A BREAKTHROUGH POSSIBILITY 
We now analyze how the possibility of a technological breakthrough in the future 
affects the current decision on the timing of evaluation and development.  From the 
previous section, the conditions that ex-post development is preferred given ex-ante 
evaluation (equation 1) and ex-post evaluation is preferred to ex-ante evaluation given 
ex-post development (equation 2) can be rewritten as follows. 
  0 ) 1 ( ) 1 ( > - f - - f ”
l - l e L d mL V  (8) 
  0 ) 1 ( ) ( > fl - - fl + l + f + ” L d mL r cr W  (9) 
 
These equations specify the parameter space in which ex-post evaluation and 
development is preferred without a breakthrough possibility.  When there exists an 
anticipated technological breakthrough, ex-ante development before a breakthrough (and 
before an infestation occurs) is always (conditional on the chosen parameter space and 
ex-ante evaluation) dominated by the development at the time of a breakthrough (
u A0 ) 
under condition (8).  Since the disease cost is low relative to the development cost, 
delaying development until the breakthrough will bring a lower cost to a genebank 
manager.  In addition, if the size of a technological breakthrough is large, delaying 
development further until the disease infestation is not optimal. That is, 
u A0  < 
t A0 if 
  V xL > f  (10) 
If the reduction in the expected development cost due to a breakthrough is large 
enough to dominate the increase in the present value of the cost due to early 
development, it is optimal to develop at the time of a breakthrough rather than to delay 
until the disease infestation.  Thus, given conditions (8), (9), and (10), ex-ante 
evaluation/post-breakthrough development (
u A0 ) is optimal if evaluation is made ex ante.  
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bracket is negative by condition (10), and the second term is negative if f(f + l) < r(r + 
b) (and if l > 0, assumed in equation (4)).  Thus, the sufficient condition where ex-ante 
evaluation is preferred is f(f + l) < r(r + b).      Q.E.D. 
Proposition 4 implies that the possibility of a technological breakthrough advances the 
timing of evaluation (and development) for f(f + l) < r(r + b).  If a technological 
breakthrough is expected to happen soon (i.e., b is high) and is likely to happen before a 
discovery occurs (i.e., f is low), this will favor early evaluation since the breakthrough 
then increases the value of immediate development.  If l is high, on the other hand, 
immediate development is likely even without a breakthrough, so the latter has less expected 
effect on timing.  Similarly, if the breakthrough happens after discovery (i.e., low b and high 
f), there is no marginal advantage to advancing evaluation to exploit the breakthrough. 
 
Figure 4:  Optimal timing of evaluation with a technological breakthrough 
 




















No action  
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Figure 4 illustrates an example of the optimal evaluation alternatives under 
different parameter spaces.  When there is no possibility of a technological breakthrough 
(x = 0), ex-ante evaluation/ex-post development (
t A0) is preferred for f > 1.18 and ex-
post evaluation (
t
t P ) for 0.25 < f < 1.18.  Within this range where ex-post evaluation is 
preferred, as the size of a breakthrough increases, the set of optimal alternatives expands 
to include post-breakthrough evaluation/development (
u
u P ) and ex-ante evaluation/post-
breakthrough development (
u A0 ).  The benefit from a large technological breakthrough 
can be substantial if it is utilized earlier.  This will induce ex-ante evaluation to capture 
the benefit of earlier utilization if condition f(f + l) < r(r + b) holds.  Thus, continuous 
advances in biotechnology in the future may induce early evaluation of genebank 
accessions and consequently early development of cultivars.  
This result is contrary to the usual argument of real option theory in which 
uncertain future environment delays the timing of a decision.  The reason for this 
difference is that in this model it takes time to utilize the breakthrough￿that is, the 
evaluation process must be successfully completed before utilizing the breakthrough in 
development.  If the evaluation process is instantaneous or the breakthrough happens in 
evaluation, our model favors delaying as in standard real option theory.  However, in 
situations where it takes time to finish the first stage of a two-stage investment process, 
the timing decision may be different from the argument of real option theory.  The ability 
to delay the second stage (development) depending on the state makes early investment 
in the first stage (evaluation) more attractive, as in Bar-Ilan and Strange (1998).  But here 
the real option value due to technological uncertainty actually can advance investment in 
both stages relative to the case of no technological uncertainty.  Bar-Ilan and Strange  
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(table 4, p.452), by contrast, find that uncertainty (in output price) increases the “trigger 
price” whether the investment may be suspended after the first stage, thus discouraging 




The agricultural environment is continuously changing, and so is the demand for 
germplasm by plant breeders.  Predicting future use of germplasm in ex-situ genebanks is 
increasingly difficult.  One of the most important policy issues regarding management of 
genebank collections concerns the evaluation of their collections prior to utilization.  A 
commonly expressed view is that all traits likely to be relevant in crop improvement 
should be completely evaluated ex ante to facilitate and encourage the utilization by plant 
breeders. 
This paper examines the optimal timing of evaluation of germplasm for disease 
resistance traits and of development of cultivars incorporating those traits, from the social 
point of view.  We consider the case where the disease-causing agent is known, but the 
date of crop infestation is stochastic.  We find that for a trait that has low probability of 
being needed soon, ex-ante evaluation tends to be dominated by delayed evaluation.  This 
result is especially important for the management of genebanks, which suffer chronic 
funding problems.  Instead of spending scarce financial resources for the expensive 
evaluation of rarely used genes, it might well be more efficient to focus on other 
activities; for example, provision of basic information and construction of an information 
network for better information flow (Frankel 1989; Williams 1989). 
Technological progress has an important influence on the timing of evaluation of 
accessions and of the development of cultivars incorporating traits identified in the 
evaluation process.  Innovations that reduce search and development costs and/or speed 
up search and development rates turn out to favor ex-ante evaluation.  The possibility of a 
future technological breakthrough in the cost of evaluation tends to delay evaluation, as  
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one might expect from the common general intuition about real option value in which 
prospective technological progress affecting the cost of an investment tends to delay the 
timing of an investment.  But the possibility of a breakthrough in the cost of development 
may advance the timing of the whole process, contrary to real option theory.  
We showed that, for the parameter space where ex-post evaluation is preferred, 
the breakthrough possibility may advance the timing of evaluation from ex post to ex 
ante.  The reason is that the marginal benefit from the technological breakthrough is 
larger when development process is started earlier.  If the initial situation favors ex-ante 
evaluation, the possibility of a breakthrough reinforces the effect on the earlier 
evaluation.  We can conclude that both the level and rate of technological progress may 
justify advancing the search process and consequently the development process, except 
when the possibility of a breakthrough refers to the evaluation stage itself.  
This study covers only one small aspect of the problems faced by genebank 
managers: i.e., evaluation for single-gene disease resistance traits.  Depending on the 
specific cost conditions, evaluation for multiple traits simultaneously might often be 
optimal, complicating the above analysis.  The case of a sequence of technological 
breakthroughs is another interesting extension.  The question of evaluation for more 
complex quantitative traits associated with yield is the subject of ongoing research in 
functional genomics.  As the science becomes better understood, exploration of the 
economics of different managerial strategies regarding genebank accessions should 
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